Arax Advisory Partners’s Pyxis Oncology PYXS Stock Holding History

Arax Advisory Partners’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42	Buy	14 +13	+1,300%	+$25	﹤0.01%	5166
2026 Q1	$20	Sell	1 -13	-93%	-$20	﹤0.01%	3718
2025 Q4	$16	Hold	14	–	–	﹤0.01%	4038
2025 Q3	$31	Buy	+14	New	+$20	﹤0.01%	3557

Other funds holding PYXS

GGI

GordonMD Global Investments Beverely Hills, California $207M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's PYXS Position: Q2 2026 in Review

Arax Advisory Partners increased its Pyxis Oncology (PYXS) stake by 1,300% in Q2 2026, buying an estimated $25 and bringing the position to 14 shares worth $42. The position accounts for ﹤0.01% of the portfolio, ranked #5166.

Arax Advisory Partners first reported a position in PYXS in Q3 2025 and has held it in 4 quarters since. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

Arax Advisory Partners held 14 shares of Pyxis Oncology worth $42 as of Q2 2026.
Arax Advisory Partners bought 13 Pyxis Oncology shares in Q2 2026, an estimated $25.
Pyxis Oncology made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5166 holding.
Arax Advisory Partners first reported a position in Pyxis Oncology in Q3 2025 and has held it in 4 quarters since.
76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.